Armed with cash from a spring financing round and a rich patent portfolio, Blueshift Biotechnologies said last week that it is steaming toward a busy first quarter in 2005: The Sunnyvale, Calif., company said it plans to launch IsoCyte, its flagship product for fluorescence-based assays.

2004 has also been a busy year for Blueshift. The biotech startup secured its first private-equity financing in April, developed and sold a prototype of IsoCyte, and forged relationships with a handful of reagent companies that may serve as potential partners down the road.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.